Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose.
Engraftment and survival following non-myeloablative allogeneic peripheral blood hematopoietic cell transplantation for malignant diseases is affected by CD8(+) T-cell dose. 46th Annual Meeting of the American-Society-of-Hematology Cao, T. M., Shizuru, J. A., Wong, R. M., Sheehan, K., Laport, G. G., Stockerl-Goldstein, K. E., JOHNSTON, L. J., Stuart, M. J., Brown, J. M., GRUMET, F. C., Negrin, R. S., Lowsky, R. AMER SOC HEMATOLOGY. 2004: 56A–56AView details for Web of Science ID 000225127500186